Study Title
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study
Study Details
Description:
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor:
Clarity PharmaceuticalsContacts:
Clarity Pharmaceuticalsclinicaltrials@claritypharmaceuticals.com
+61 (0) 2 9209 4037
Government Study Link:
NCT06056830 - Click here to see study onClinicalTrials.gov
Inclusion
- • Untreated, histologically confirmed adenocarcinoma of the prostate
- • High-risk or greater PC defined by National Comprehensive Cancer Network Guidelines Version 1.2023
- • Patients electing to undergo RP with PLND.
Exclusion
- •Patients with known predominant small cell or neuroendocrine PC
- •Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedure
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
United States
Australia